Last updated 7 days ago

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

350 patients around the world

Available in Argentina, United States

Eli Lilly and Company

1Research sites

350Patients around the world

This study is for people with

Obesity

Diabetes

Diabetes mellitus type 2

Requirements for the patient

To 75 Years

All Gender

Medical requirements

: Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²).
Have Type 2 Diabetes.
Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening.
Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss).

: Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening.
Have an on-going or history of bradyarrhythmia and/or sinus bradycardia.
Have an elevated resting pulse rate (mean >100 beats per minute (bpm)) or reduced resting pulse rate (mean <60 bpm) at screening.
Have any of the following cardiovascular conditions within 6 months prior to screening: acute myocardial infarction.
Have any of the following cardiovascular conditions within 6 months prior to screening: cerebrovascular accident (stroke).
Have any of the following cardiovascular conditions within 6 months prior to screening: unstable angina.
Have any of the following cardiovascular conditions within 6 months prior to screening: hospitalization due to congestive heart failure.
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliters per minute (mL/min)/1.73 m2.
Have a history of acute or chronic pancreatitis.
Have fasting triglycerides >500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening.
All concomitant medications should be at a stable dose for at least 3 months prior to screening.
Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
Have poorly controlled hypertension.
Have a history of symptomatic gallbladder disease within the past 2 years.
Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
Have a lifetime history of suicide attempts.

Sites

Centro Médico Maffei - CABA, Buenos Aires

Recruiting

Av. Cerviño 3375, CABA, Buenos Aires

SponsorEli Lilly and Company

Study typeInterventional

Conditions

ObesityDiabetes mellitus type 2

Requirements

To 75 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06603571